• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    BetterInvesting™ Magazine Update on Stride Inc. (NYSE: LRN) and Amgen Inc. (NASDAQ: AMGN)

    5/27/25 10:18:00 PM ET
    $AMGN
    $LRN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Other Consumer Services
    Real Estate
    Get the next $AMGN alert in real time by email

    TROY, Mich., May 27, 2025 /PRNewswire/ -- Stride Inc.'s recent report has investors wondering if the company's stock is overvalued. Or is it in the buy range? As such, the Editorial Advisory and Securities Review Committee of BetterInvesting Magazine considers Stride Inc. (NYSE:LRN) as worthy of further study and has named the company its "Stock to Study" for the August 2025 issue for investors' informational and educational use.

    The fundamental data is eye-opening; investors can view Stride's sales, earnings, pre-tax profit, return on equity, and more all on one page, courtesy of the National Association of Investors Corp., here. 

    A full report on Stride will appear in the August 2025 issue of BetterInvesting Magazine. 

    The same issue of BetterInvesting Magazine will also include a fundamental review of Amgen Inc. (NASDAQ:AMGN), which the independent Editorial Advisory and Securities Review Committee believes is worthy of further study from an undervalued perspective. 

    Committee members are Daniel J. Boyle, CFA; Marisa Bradbury, CFA; Philip Keating, CFA; Walter J. Kirchberger, CFA; Anne Nichols, CFA; and Dan Rutter, CFA.

    Doron P. Levin, an editor of the magazine, serves as the committee's chairperson.

    Securities mentioned are for study and presented for educational purposes only. They are not to be considered as endorsed or recommended for purchase by NAIC/BetterInvesting. Investors should conduct their own review and analysis of any company of interest using the Stock Selection Guide before making an investment decision.

    About BetterInvesting:

    BetterInvesting™, a national 501(c)(3) nonprofit, investment education organization, has been empowering everyday Americans since 1951. Also known as the National Association of Investors™ (NAIC®), we have helped more than 5 million people from all walks of life learn how to improve their financial future. BetterInvesting provides unbiased, in-depth investing education and powerful online stock analysis tools to create successful lifelong investors. BetterInvesting staff, along with a dedicated community of volunteers across America, teach the organization's principles and time-tested methodology to individuals and investment clubs. For more information about BetterInvesting, please visit www.betterinvesting.org

    Follow us on LinkedIn, Instagram and Facebook.

    Contact: 877-275-6242

    Cision View original content:https://www.prnewswire.com/news-releases/betterinvesting-magazine-update-on-stride-inc-nyse-lrn-and-amgen-inc-nasdaq-amgn-302466516.html

    SOURCE NAIC-BetterInvesting

    Get the next $AMGN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMGN
    $LRN

    CompanyDatePrice TargetRatingAnalyst
    Amgen Inc.
    $AMGN
    5/20/2025$288.00Neutral
    Guggenheim
    Amgen Inc.
    $AMGN
    4/22/2025$305.00Neutral
    Cantor Fitzgerald
    Amgen Inc.
    $AMGN
    12/10/2024$256.00Underperform
    BofA Securities
    Amgen Inc.
    $AMGN
    11/15/2024Peer Perform
    Wolfe Research
    Amgen Inc.
    $AMGN
    11/14/2024$335.00Neutral
    Citigroup
    Amgen Inc.
    $AMGN
    10/17/2024$380.00Outperform
    Bernstein
    Amgen Inc.
    $AMGN
    10/14/2024$320.00 → $333.00Buy → Hold
    Truist
    Amgen Inc.
    $AMGN
    9/27/2024$405.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $AMGN
    $LRN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for REPATHA issued to AMGEN INC

    Submission status for AMGEN INC's drug REPATHA (SUPPL-44) with active ingredient EVOLOCUMAB has changed to 'Approval' on 11/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

    11/21/24 12:43:07 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for PAVBLU issued to AMGEN INC

    Submission status for AMGEN INC's drug PAVBLU (ORIG-1) with active ingredient AFLIBERCEPT has changed to 'Approval' on 08/23/2024. Application Category: BLA, Application Number: 761298, Application Classification:

    8/26/24 5:53:38 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for REPATHA issued to AMGEN INC

    Submission status for AMGEN INC's drug REPATHA (SUPPL-43) with active ingredient EVOLOCUMAB has changed to 'Approval' on 08/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

    8/21/24 12:12:47 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMGN
    $LRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Rhyu James Jeaho covered exercise/tax liability with 6,128 shares, decreasing direct ownership by 0.83% to 729,596 units (SEC Form 4)

    4 - Stride, Inc. (0001157408) (Issuer)

    8/14/25 5:27:56 PM ET
    $LRN
    Other Consumer Services
    Real Estate

    MANAGING DIRECTOR Goldthwaite Todd covered exercise/tax liability with 410 shares, decreasing direct ownership by 0.45% to 90,894 units (SEC Form 4)

    4 - Stride, Inc. (0001157408) (Issuer)

    8/14/25 5:26:43 PM ET
    $LRN
    Other Consumer Services
    Real Estate

    CHIEF FINANCIAL OFFICER Blackman Donna covered exercise/tax liability with 2,508 shares, decreasing direct ownership by 2% to 112,189 units (SEC Form 4)

    4 - Stride, Inc. (0001157408) (Issuer)

    8/14/25 5:25:48 PM ET
    $LRN
    Other Consumer Services
    Real Estate

    $AMGN
    $LRN
    SEC Filings

    View All

    Stride Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Stride, Inc. (0001157408) (Filer)

    8/5/25 4:15:31 PM ET
    $LRN
    Other Consumer Services
    Real Estate

    Amgen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - AMGEN INC (0000318154) (Filer)

    8/5/25 4:03:34 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 11-K filed by Amgen Inc.

    11-K - AMGEN INC (0000318154) (Filer)

    6/12/25 4:46:22 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMGN
    $LRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim resumed coverage on Amgen with a new price target

    Guggenheim resumed coverage of Amgen with a rating of Neutral and set a new price target of $288.00

    5/20/25 8:11:08 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cantor Fitzgerald resumed coverage on Amgen with a new price target

    Cantor Fitzgerald resumed coverage of Amgen with a rating of Neutral and set a new price target of $305.00

    4/22/25 7:29:10 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BofA Securities resumed coverage on Amgen with a new price target

    BofA Securities resumed coverage of Amgen with a rating of Underperform and set a new price target of $256.00

    12/10/24 8:12:28 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMGN
    $LRN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators

    NetworkNewsWire Editorial Coverage NEW YORK, Aug. 6, 2025 /PRNewswire/ -- As the American population gets older, chronic and rare diseases are becoming a significant healthcare issue, particularly for older adults. The aging population's increasing life expectancy also leads to more complex healthcare needs, especially for conditions that are both chronic and difficult to diagnose. Many of these rare conditions lack FDA-approved treatments, and their symptoms in seniors are frequently mistaken for normal signs of aging, causing diagnostic delays that can last for years. There are more than 30 million Americans who have a rare disease, so there is a growing need for accurate diagnoses and eff

    8/6/25 8:30:00 AM ET
    $AMGN
    $CTOR
    $FOLD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Stride Achieves Another Record Year

    RESTON, Va., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Stride, Inc. (NYSE:LRN), one of the nation's most successful technology-based education companies, today announced its results for the fourth quarter and full fiscal year ended June 30, 2025. Fiscal 2025 Highlights Compared to 2024 Revenue of $2,405.3 million, compared with $2,040.1 millionIncome from operations of $360.1 million, compared with $249.6 millionNet income of $287.9 million, compared with $204.2 millionDiluted net income per share of $5.95, compared with $4.69Adjusted operating income of $466.2 million, compared with $293.9 million (1)Adjusted EBITDA of $571.0 million, compared with $390.7 million (1)Adjusted earnings per share

    8/5/25 4:15:00 PM ET
    $LRN
    Other Consumer Services
    Real Estate

    AMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

    THOUSAND OAKS, Calif., Aug. 5, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2025.  "We're delivering strong performance and reaching more patients with innovative medicines and biosimilars that address serious diseases. We continue to invest in science that enables longer, healthier lives and supports sustainable, long-term growth," said Robert A. Bradway, chairman and chief executive officer. Key results include: For the second quarter, total revenues increased 9% to $9.2 billion in comparison to the second quarter of 2024.Product sales grew 9%, driven by 13% volume growth, partially offset by 3% lower net selling price.Fifteen product

    8/5/25 4:01:00 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMGN
    $LRN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Amgen Inc converted options into 33,603,948 shares and bought $29,999,985 worth of shares (1,764,705 units at $17.00)

    4 - AMGEN INC (0000318154) (Reporting)

    9/19/23 7:52:07 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMGN
    $LRN
    Financials

    Live finance-specific insights

    View All

    Stride Achieves Another Record Year

    RESTON, Va., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Stride, Inc. (NYSE:LRN), one of the nation's most successful technology-based education companies, today announced its results for the fourth quarter and full fiscal year ended June 30, 2025. Fiscal 2025 Highlights Compared to 2024 Revenue of $2,405.3 million, compared with $2,040.1 millionIncome from operations of $360.1 million, compared with $249.6 millionNet income of $287.9 million, compared with $204.2 millionDiluted net income per share of $5.95, compared with $4.69Adjusted operating income of $466.2 million, compared with $293.9 million (1)Adjusted EBITDA of $571.0 million, compared with $390.7 million (1)Adjusted earnings per share

    8/5/25 4:15:00 PM ET
    $LRN
    Other Consumer Services
    Real Estate

    AMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

    THOUSAND OAKS, Calif., Aug. 5, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2025.  "We're delivering strong performance and reaching more patients with innovative medicines and biosimilars that address serious diseases. We continue to invest in science that enables longer, healthier lives and supports sustainable, long-term growth," said Robert A. Bradway, chairman and chief executive officer. Key results include: For the second quarter, total revenues increased 9% to $9.2 billion in comparison to the second quarter of 2024.Product sales grew 9%, driven by 13% volume growth, partially offset by 3% lower net selling price.Fifteen product

    8/5/25 4:01:00 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AMGEN ANNOUNCES 2025 THIRD QUARTER DIVIDEND

    THOUSAND OAKS, Calif., Aug. 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the third quarter of 2025. The dividend will be paid on September 12, 2025, to all stockholders of record as of the close of business on August 22, 2025. About Amgen   Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is adv

    8/1/25 4:01:00 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMGN
    $LRN
    Leadership Updates

    Live Leadership Updates

    View All

    NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer

    NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer Former Amgen, Novo Nordisk and Boehringer Ingelheim senior leader joins NodThera Leadership TeamWill spearhead clinical advancement of the company's innovative NLRP3 inflammasome inhibitor portfolioBrings deep clinical leadership in obesity and cardiometabolic diseases, with a proven track record guiding programs from early-stage development through Phase 3 and regulatory approval Philadelphia, PA, July 21, 2025 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the appoi

    7/21/25 7:00:00 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    GeminiBio Appoints Mike Stella to Board

    Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

    2/18/25 9:00:00 AM ET
    $AMGN
    $GSK
    $JNJ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    Opening Doors to Healthcare Careers: McKallen Medical Training Center Partners with MedCerts to Expand Access to Training Programs for Aspiring Healthcare Professionals

    ONTARIO, California, Nov. 13, 2024 (GLOBE NEWSWIRE) -- As the demand for skilled healthcare professionals surges in California, McKallen Medical Training Center (MMTC) is stepping up to meet the challenge. MMTC is teaming up with MedCerts, a recognized leader in online healthcare training, to offer a wide range of certification training courses to aspiring healthcare workers. This collaboration will provide students with access to quality, flexible online certification training in critical areas like Medical Assistant, Patient Care Technician and more, helping to fill essential roles in California's rapidly growing healthcare industry. MMTC currently offers programs at its locations in

    11/13/24 9:00:00 AM ET
    $LRN
    Other Consumer Services
    Real Estate

    $AMGN
    $LRN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Stride Inc.

    SC 13G/A - Stride, Inc. (0001157408) (Subject)

    10/31/24 11:54:57 AM ET
    $LRN
    Other Consumer Services
    Real Estate

    SEC Form SC 13G/A filed by Amgen Inc. (Amendment)

    SC 13G/A - AMGEN INC (0000318154) (Subject)

    2/13/24 4:58:51 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Amgen Inc. (Amendment)

    SC 13G/A - AMGEN INC (0000318154) (Subject)

    1/30/24 11:35:57 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care